国际肿瘤学杂志

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (8): 652-655.doi: 10.3760/cma.j.issn.1673422X.2017.09.003

• 论著 • 上一篇    下一篇

长非编码RNA SBF2-AS1在非小细胞肺癌中的表达和临床意义

彭琦,陈辅萍,党晓敏   

  1. 726000 陕西省商洛市中心医院呼吸内科（彭琦、陈辅萍）；西安交通大学第一附属医院呼吸与危重症医学科（党晓敏）
  • 出版日期:2017-09-08 发布日期:2017-10-31
  • 通讯作者: 党晓敏，Email: dxming112@163.com E-mail:dxming112@163.com

Expression and clinical significance of long non-coding RNA SBF2-AS1 in nonsmall cell lung cancer

Peng Qi, Chen Fuping, Dang Xiaomin   

  1. Department of Respiration, Shangluo Central Hospital of Shaanxi Province, Shangluo 726000, China
  • Online:2017-09-08 Published:2017-10-31
  • Contact: Dang Xiaomin E-mail:dxming112@163.com

PDF

609

摘要： 目的探讨非小细胞肺癌（NSCLC）组织中长非编码RNA SBF2AS1的表达及临床意义。方法采用实时荧光定量聚合酶链反应（qRTPCR）方法检测114例新鲜NSCLC组织标本及相对应的正常癌旁组织标本中SBF2AS1的表达，分析其与NSCLC临床病理特征及诊断和预后的关系。结果SBF2AS1在NSCLC组织中的表达（4.336±0.032）显著高于癌旁正常组织（1.256±0.021），差异有统计学意义（t=3.594，P=0.005）。SBF2AS1表达与NSCLC的肿瘤大小（χ2=13.072，P=0.001）、淋巴结转移（χ2=6.896，P=0.009）、疾病分期（χ2=8.566，P=0.003）、吸烟史（χ2=8.769，P=0.003）、浸润深度（χ2=17.852，P=0.001）有关，而与年龄（χ2=0.141，P=0.707）、性别（χ2=0.036，P=0.850）、病理类型（χ2=1.267，P=0.260）无关。受试者工作特征（ROC）曲线分析显示曲线下面积为0.853（95%CI为0.755～0.879，P=0.004），敏感性和特异性分别为52.4%和87.8%。SBF2AS1低表达和高表达组患者在中位总生存时间的差异具有统计学意义（42.3个月∶25.2个月，χ2=4.753，P=0.013）。结论SBF2AS1在NSCLC中高表达，可作为治疗NSCLC的新型生物标志物和诊断靶标。

关键词: 肺肿瘤, 病理学, 临床, 生物学标记, 药理学, SBF2-AS1

Abstract: ObjectiveTo investigate the expression and clinical significance of long noncoding RNA SBF2AS1 (SBF2 antisense RNA 1) in nonsmall cell lung cancer (NSCLC). MethodsRealtime quantitative polymerase chain reaction (qRTPCR) was used to detect SBF2AS1 expressions in 114 cases of NSCLC tissues and the adjacent normal tissues to analyze its relationship with clinicpathological characteristics, diagnostic value and prognosis in NSCLC. Results SBF2AS1 expression was significantly higher in the NSCLC (4.336±0.032) compared with the adjacent normal tissues (1.256±0.021), with a significant difference (t=3.594, P=0.005). The expression of SBF2AS1 was related with tumor size (χ2=13.072, P=0.001), lymphatic metastasis (χ2=6.896, P=0.009), TNM stage (χ2=8.566, P=0.003), smoking history (χ2=8.769, P=0.003) and infiltration degree (χ2=17.852, P=0.001), but was not related with age (χ2=0.141, P=0.707), sex (χ2=0.036, P=0.850) and pathological type (χ2=1.267, P=0.260). The area under the receiver operating characteristic (ROC) curve was 0.853 (95%CI: 0.7550.879, P=0.004). The sensitivity and specificity was 52.4% and 87.8%, respectively. The difference betwen low SBF2AS1 expression and high SBF2AS1 expression groups was statistically significant in overall survival time (42.3 months vs. 25.2 months, χ2=4.753, P=0.013). ConclusionThe expression of SBF2AS1 is upregulated in NSCLC and may be proved useful as a biomarker and diagnostic target for the treatment of patients with NSCLC.

Key words: Lung neoplasms, Pathology, clinical, Biomarkers, pharmacological, SBF2-AS1